Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Stock Information for Candel Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Candel Therapeutics Inc.

Candel Therapeutics Announces Pricing of Public Offering
Candel Therapeutics Announces Proposed $100 Million Public Offering
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.